Carcinogenesis and cyclooxygenase: The potential role of COX-2 inhibition in upper aerodigestive tract cancer

Oral Oncology

Volumn 39, Issue 6, 2003, Pages 537-546

  Mohan, Sivani ^a   Epstein, Joel B ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Chemoprevention COX 2 inhibitors; Cyclooxygenase 2; Upper aerodigestive tract cancer

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E2; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LITERATURE; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; NONHUMAN; PRECANCER; PRELIMINARY COMMUNICATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; STOMACH IRRITATION; STOMACH ULCER; UPPER RESPIRATORY TRACT; UPREGULATION;

EID: 0038460053     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(03)00035-6     Document Type: Review

References (131)

1. Moore S.R., Johnson N.W., Pierce A.M., Wilson D.F. The epidemiology of tongue cancer. a review of global incidence Oral Disease. 6:2000;75-84.
2. Johnson N. Oral cancer. a world wide problem FDI World. 6:1997;19-21.
3. Atula S., Grenman R., Laippala P., Syrjanen S. Cancer of the tongue in patients younger than 40 years. A distinct entity? Arch Otolaryngol Head Neck Surg. 122:1996;1313-1319.
4. Macfarlane G.J., Macfarlane T.V., Lowenfels A.B. The influence of alcohol consumption on worldwide trends in mortality from upper aero digestive tract cancers in men. J Epidemiol Community Health. 50:1996;636-639.
5. Epstein J.B., Zhang L., Rosin M. Advances in the diagnosis of oral premalignant and malignant lesions. J Canad Dent Assoc. 68:2002;617-621.
6. Scully C., Field J.K., Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinico-pathological applications. Oral Oncol. 36:2000;404-413.
7. Scully C., Field J.K., Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. Oral Oncol. 36:2000;311-327.
8. Scully C., Field J.K., Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 36:2000;256-263.
9. Herschman H.R. Prostaglandin synthetase-2. Biochim Biophys Acta. 1299:1996;125-140.
10. Kutchera W., Jones D.A., Matsunami N., Groden J., McIntyre T.M., Zimmerman G.A., White R.L.et al. Prostaglandin H synthase-2 is expressed abnormally in human colon cancer. evidence of transcriptional effect Proc Natl Acd Sci USA. 93:1996;4816-4820.
11. Eberhart C.E., Coffey R.J., Radhika F.M., Giardello S., Ferenbach S., DuBois R.N. Up-egulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterol. 107:1996;1183-1188.
12. Hida T., Yatabe Y., Muramatsu H., Kozaki K., Nakamura S., Ogawa M.et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:1998;3761-3764.
13. Smalley W., DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol. 30:1997;1-20.
14. Sheng H., Shao J., Kirkland S.C., Isakson P., Coffey R.J., Morrow J.et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 9:1997;2254-2259.
15. Jackel E.C., Raja S., Tan J., Das S.K., Dey S.K., Griod D.A.et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, peroxisome proliferator-activated receptor (delta) with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 127:2001;1253-1259.
16. Gupta R.A., DuBois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Rev Cancer. 1:2001;11-21.
17. Nishimura G., Yanoma S., Mizuno H., Kawakami K., Tsukuda M. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Japan J Cancer Res. 90:1999;1152-1162.
18. Shiotani H., Denda A., Yamamoto K., Kitayama W., Endoh T., Sasaki Y.et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline 1-oxide induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor nimesulide. Cancer Res. 61:2001;1451-1456.
19. Smith W.L., Dewitt D.L., Garavito R.M. Cyclooxygenase. structural, cellular and molecular biology Ann Rev Biochem. 69:2000;145-182.
20. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases (cycloxygenases)-1& 2. J Biol Chem. 271:1996;33157-33160.
21. Waddell W.R., Miesfeld R.L. Adenomatous polyposis coli, protein kinase, protein tyrosine phosphate. J Surg Oncol. 58:1995;252-256.
22. Rubio C.A. Further studies on the therapeutic effect of indomethacin on esophageal tumors. Cancer. 58:1986;1116-1119.
23. Coogan P.F., Rosenberg L., Louik C., Zauber A.G., Stolley P.D., Strom B.L., Shapiro S. Nonsteroidal anti-inflammatory drugs and risk of digestive cancer sites other than the bowel. Cancer Epidemiol Biomark Prev. 9:2000;119-123.
24. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 90:1998;455-460.
25. Tucker O.N., Dannerberg A.J., Yang E.K., Zang F., Teng L., Daly J.M.et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59:1999;987-990.
26. Wolf H., Saukkonenk A.S., Karajalainen A., Vairo H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:1998;4997-5001.
27. Buckman S.Y., Gresham A., Hale P., Hruza G., Anast J., Masferrer J., Pentland A.P. Cox-2 expression is induced by UVB exposure in human skin. implications for the development of skin cancer Carcinogenesis. 19:1998;723-729.
28. Mohammed S.I., Knapp D.W., Bostwick D.G., Foster R.N., Khan K.N., Masferrer J.et al. Expression of cyclooxygenase-2 (Cox2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 59:1999;5647-5650.
29. Gupta S., Srivastava M., Ahmad N., Bostwick D.G., Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 42:2000;73-78.
30. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E.et al. Suppression of intestinal polyposis in APC76 knockout mice by inhibition of cyclooxygenase-2. Cell. 87:1996;803-809.
31. Tiano H.F., Loftin C.D., Akunda J., Lee C.A., Spalding J., Sessoms A.et al. Deficiency of either cyclooxygenase (COX-1) or (COX-2) alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62:2002;3395-3401.
32. DuBois R.N., Awed J., Morrow J., Roberts II J.I., Bishop P.R. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor- alpha and phorbal ester. J Clinic Invest. 93:1994;493.
33. Chang G., Boyle J.O., Eun K.Y., Zhang F., Peter G.S., Jatin P.S.et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59:1999;991-994.
34. Shin D.M., Charuruks N., Lippman S.M., Lee J.J., Ro J.Y., Hong W.K., Hittelman W.N. P53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Bio Prevent. 10:2001;603-609.
35. Subbaramiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., Jang M.et al. Resveratol inhibits cyclooxgenase-2 transcription activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem. 273:1998;21875-21882.
36. Kunkel S.L., Wiggins R.C., Chensue S.W., Larrick J. Regulation of macrophage tumor necrosis factor production by prostaglandinE2. Biochem. Biophys. Res. Commun. 137:1986;404-410.
37. Kambayashi T., Alexander A.R., Fong M., Strassman G. Potential involvement of IL-10 in suppressing tumor associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via mechanism involving IL-10. J Immunol. 154:1995;3383-3390.
38. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Lou J.et al. Specific inhibition of cycloooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 164:2000;361-370.
39. Tsujii M., DuBois R.N. Alteration in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell. 83:1995;493-501.
40. Rosenberg L., Palmer J.R., Shapiro S. Aspirin use and incidence of large bowel cancer in a California retirement community. J Nat Cancer Inst. 83:1991;1182-1183.
41. Sheng H., Shao J.D., Morrow J., Beachamp R.D., Dubois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58:1998;362-366.
42. Wattenberg L.W. Inhibition of carcinogenesis and toxic effects of polycyclic hydrocarbons by phenolic antioxidants and ethoxyquin. J Nat Cancer Inst. 48:1973;1425-1430.
43. Loro L.L., Johannessen A.C., Vintermyr O.K. Decreased expression of bcl-2 in moderate and severe oral epithelial dysplasias. Oral Oncol. 38:2002;691-698.
44. Hong W., Lippman S.M., Itri L.M., Karp D.D., Lee J.S., Byers R.M.et al. Prevention of secondary primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 323:1990;795-801.
45. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A. Inhibition of cyclooxygenase-2 gene expression by p53. J Bio Chem. 274:1999;10911-10915.
46. Li H.L., Zhang H.W., Chen D.D., Zhong L., Ren X.D., Si-Tu R. JTE522, a selective Cox-2 inhibitor, inhibits cell proliferation and induces apoptosis in RL95-2 cells. Acta Pharmacol Sin. 23:2002;631-637.
47. Jaeckel E.C., Raja S., Tan J., Das S.K., Dey S.K., Girod D.A.et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferators-activated receptor (delta) with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 127:2001;1253-1259.
48. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
49. Williams C.S., Tsujii M., Reese J., Dey S.K., DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 105:2000;1589-1594.
50. Chen Y.J., Jin Y.T., Shieh D.B., Tsai S.T., Wu L.W. Molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells. Oral Oncol. 38:2002;699-705.
51. Jablonska E., Piotrowski L., Jablonska J., Grabowska Z. VEGF in the culture of PMN and the serum in oral cavity cancer patients. Oral Oncol. 38:2002;6055-6059.
52. Shemirani B., Crowe D.L. Hypoxic induction of HIF1alpha and VEGF expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases. Oral Oncol. 38:2002;251-257.
53. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci. 94:1997;3336-3340.
54. Dohadwala M., Luo J., Zhu L., Lin Y., Dougherty G.J., Sharma S., Huang M. Non-small cell lung cancer cyclooxygenase-2 dependent invasion is mediated by CD44. J Biol Chem. 276:2001;20809-20812.
55. Tomozawa S., Nagawa H., Tsuno N., Hatano K., Osada L., Kitayama J.et al. Inhibition of hematogenous metastasis of colon cancer in mice by a selective Cox-2 inhibitor, JTE522. Br J Cancer. 81:1999;1274-1279.
56. Janot F.B., Massaad L., Ribrag V., De Waaziers I., Beaune P.H., Luboinski B.et al. Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinoma. Carcinogenesis. 14:1993;1279-1283.
57. Eling T.E., Thompson D.C., Foreman G.L., Curtis J.F., Hughes M.F. Prostaglandin H synthase and xenobiotics. Ann. Rev Pharmacol Toxicol. 30:1990;1-45.
58. Wattenberg L.W. Chemoprevention of Cancer. Cancer Res. 45:1985;1-8.
59. Kelley D.J., Mestre J.R., Subramaniak K., Sacks P.G., Schantz S.P., Tanabe T.et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis. 18:1997;795-799.
60. Andrew J.D., Nasser K.A., Boyle J.O., Derrick T., Subbaramiah K. Inhibition of cyclooxygenase-2. an approach to preventing cancer of the upper aerodigestive tract Ann NY Acad Sci. 952:2001;109-115.
61. Mestre J.R., Chan G., Zhang F., Yang E.K., Sacks P.G., Boyle J.O.et al. Inhibition of cyclooxygenase-2 expression. an approach to preventing head and neck cancer Annals NY Acad Sci. 889:1999;62-71.
62. Chan G., Boyle J.O., Yang E.K., Zhang F., Sacks P.G., Shah J.P.et al. Cyclooxygenase-2 expression up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59:1999;991-994.
63. Jung T.T.K., Berlinger N.T., Juhn S.K. Prostaglandins in squamous cell carcinoma of the head and neck; preliminary study. Laryngoscope. 95:1985;307-312.
64. Tanaka T., Nishikawa A., Mori Y., Morishita M., Mori H. Inhibitory effects of non- steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Let. 48:1989;177-182.
65. Perkins T.M., Shklar G. Delay in hamster pouch carcinogenesis by aspirin and indomethacin. Oral Surg Oral Med Oral Pathol. 53:1982;170-178.
66. Karmali R.A., Wustrow T., Thaler H.T., Strong E.W. Prostaglandins in carcinoma of the head and neck. Cancer Let. 22:1984;333-336.
67. Kishi K., Petersen S., Petersen C., Hunter N., Masson K. Preferential enhancement response by a cyclooxygenase-2 inhibitor. Cancer Res. 60:2000;1326-1331.
68. Lin D.T., Subbaramaiah K., Shah J.P., Dannenberg A.J., Boyle J.O. Cyclooxygenase-2. a novel molecular target for the prevention and treatment of head and neck cancer Head Neck. 24:2002;792-799.
69. Renkonen J., Wolff H., Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and precursor lesions. Virchows Archiv. 440:2002;594-597.
70. Sumitani K., Kamijo R., Toyoshima T., Nakanishi Y., Takizawa K., Hatori M.et al. Specific inhibition of cycloooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med. 30:2001;441-447.
71. Jeng J.H., Ho Y.S., Chan C.P., Wang Y.J., Hahn L.J., Lei D.et al. Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes. Carcinogenesis. 21:2000;1365-1370.
72. Cross D.S., Platt J.L., Juhn S.K., Bach F.H., Adams G.L. Tumor infiltrating lymphocytes in squamous cell carcinoma of the head and neck; mechanism of enhancement using prostaglandin synthetase inhibitors. Advance Exper Med Biol. 400:1997;1013-1024.
73. Huang M., Stolina M., Sharma S., Mao T., Zhu L., Miller P.W.et al. Non-small cell lung cancer cyclooxygenase-2 dependent up-regulation of cytokine balance in lymphocytes and macrophages. up regulation of interleukin 10 and down- regulation of interleukin 12 production Cancer Res. 58:1998;1208-1216.
74. Gallo O., Franchi A., Magnelli L., Sardi L., Boddi V., Chiarugi V., Masini E. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for angiogenesis and metastasis Neoplasia. 3:2001;53-61.
75. Oriate N., Lotan D., Xu X.C., Hong W.K., Lotan R. Differential induction of apoptosis by all trans-retinoic acid and n-(4-hydroxyphenyl) retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res. 2:1993;855-863.
76. Mestre J.R., Subbaramaiah K., Sacks P.G., Stimson P., Schantz S.P., Tanabe T.et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res. 57:1997;2890-2895.
77. Grandis J.R., Tweardy D.J. Elevated levels of transforming growth factor-(alpha) and epidermal growth factor messenger mRNA as early markers of carcinogenesis in head and neck cancer. Cancer Res. 53:1993;3579-3584.
78. Shin D.M., Ro J.Y., Hong W.K., Hittleman W.N. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 54:1994;3153-3159.
79. O-charoenrat P., Rhys-Evans P.H., Modjtahedi H., Eccles S.A. The role of c-erb receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol. 38:2002;627-640.
80. Nagatsuka H., Ishiwari Y., Tsujigiwa H., Nakano K., Nagai N. Quantitation of epidermal growth factor receptor gene amplification by competitive polymerase chain reaction in pre-malignant and malignant oral epithelial lesions. Oral Oncol. 37:2001;599-604.
81. Kelloff G.J., Fay J.R., Steele V.E., Lubet R.A., Boone C.W., Crowell J.A.et al. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 5:1996;657-666.
82. Moon R.C., McCormick D.L., Metha R.G. Inhibition of carcinogenesis by retinoids. Cancer Res. 43:1983;2469-2475.
83. Mestre J.R., Subbaramaiah K., Sacks P.G., Schantz S.P., Tanabe T., Inoue H.et al. Retinoids suppress phorbal ester-mediated induction of cyclooxygenase-2. Cancer Res. 57:1997;1081-1085.
84. Zou C.P., Clifford J.L., Xu C.X., Sacks P.G., Chambon P., Hong W.K.et al. Modulation by retinoic acid of squamous cell differentiation, cellular RA-binding proteins, and nuclear RA receptors in human head and neck squamous cell carcinoma lines. Cancer Res. 54:1994;5479-5487.
85. Hong W.K., Endicott J., Itri L.M., Doos W., Batsakis J.G., Bell R.et al. 13-cis- retinoic acid in the treatment of oral leukoplakia. N Eng J Med. 315:1986;1501-1505.
86. Klassen I., Braakhuis B.J. Anticancer activity and mechanism of action of retinoids in oral and pharyngeal cancer. Oral Oncol. 38:2002;532-542.
87. Epstein J.B., Gorsky M. Topical application of vitamin A to oral leukoplakia. a clinical case series Cancer. 86(6):1999;921-927.
88. Gorsky M., Epstein J.B. The effect of retinoids on oral premalignant lesions. Focus on topical therapy Cancer. 15(95):2002;1258-1264.
89. Suh O., Mettlin C., Petrelli N.J. Aspirin use, cancer, and polyps of the large bowel. Cancer. 72:1993;1171-1177.
90. Peleg I., Maibach H.T., Wilcox C.M. Aspirin and nonsteroidal anti-inflammatory drug (NSAID). Use and the risk of subsequent colorectal polyps Gastentroenterol. 104:1993;A440.
91. Schreinemachers D.M., Everson R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiol. 5:1994;138-146.
92. Thun M.J., Namboodiri M.M., Heath C.W. Jr. Aspirin use and reduced risk of fatal colon cancer. N Eng J Med. 325:1991;1593-1596.
93. Reeves M.J., Newcomb P.A., Trentham-Dietz A., Storer B.E., Remington P.L. Non-steroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 5:1996;955-960.
94. Muscat J.E., Stellman S.D., Wynder E.L. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer. 74:1994;1847-1854.
95. Kune G.A., Kune S., Watson L.F. Colorectal cancer risk, chronic illness. operations and medications: case control from the Melbourne Colorectal Cancer Study Cancer Res. 48:1988;4399-4404.
96. Hussey H.J., Tisdale M.J. Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumor growth and cachexia in a murine model. Int J Cancer. 87:2000;95-100.
97. Fosslien E. Biochemistry of cyclooxygenase-2 (COX-2) inhibitors and molecular pathology of cox-2 in neoplasia. Crit Rev Clin Lab Sci. 37:2000;431-502.
98. Kawamori T., Rao C.V., Seibert K., Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor against colon carcinogenesis. Cancer Res. 58:1998;409-412.
99. Paik J.H., . Ju J.H., Lee J.Y., Boudreau M.D., Hwang D.H. Two opposing effects of non-steroidal anti inflammatory drugs on the expression of mitogen inducible cyclooxygenase. Mediation through different signaling pathways. J Biol Chem. 275:2000;28173-28179.
100. Mutoh M., Takahashi M., Fukuda K., Komatsu H., Enya T., Mutoh H.et al. Suppression by flavinoids of cyclooxygenase-2 promoter-dependent transcription activity in colon cancer cells. structure activity relationship Japan J Cancer Res. 91:2000;689-691.
101. Reddy B.S., Hirose Y., Lubert R., Steele V., Kelloff G., Paulson S.et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor celecoxib administered during different stages of carcinogenesis. Cancer Res. 60:2000;293-297.
102. Steinbach G., Lynch P.M., Phillips R.K.S., Wallace M.H. The effect of Celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Eng J Med. 342:2000;1946-1952.
103. DuBois R.N., Gupta R., Brockman J., Reddy B.S., Krakow S.L., Lazar M.A. The nuclear eicosanoid receptor, PPRAgamma, is aberrantly expressed in colonic cancers. Carcinogenesis. 19:1998;49-53.
104. Wang Z., Fuentes C.F., Stanley M., Shapshay S.M. Antiangiogenic and chemopreventive activities of Celecoxib in oral carcinoma cell. Laryngoscope. 112:2002;839-843.
105. Lee D.W., Sung M.W., Park S.W., Seong W.J., Roh J.L., Park B.et al. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of head and neck. Inhibition of proliferation by nonsteroidal anti-inflammatory drugs Anticancer Res. 22:2002;2089-2096.
106. Panje W.R. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol. 107:1981;658-663.
107. Dicker A.P., Williams T.L., Grant D.S. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol. 24:2001;438-442.
108. Milas L., Kishi K., Hunter N., Mason K., Masferrer J.L., Tofilon P.J. Enhancement of tumor response to gamma radiation by an inhibitor of cyclooxygenase-2 enzyme. J Nat Cancer Inst. 91:1999;1501-1504.
109. Toyoshima T., Kamijo R., Takizawa K., Sumitini K., Ito D., Nagumo M. Inhibition of cyclooxygenase-2 induces cell cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Brit J Cancer. 86:2000;1150-1156.
110. Nikitakis N.G., Herbert C., Lopes M.A., Sauk J.J. PPAR gamma-mediated antineoplastic effect of the NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer. 98:2002;817-823.
111. Subbaramaiah K., Michaluart P.K., Sporn M.B., Dannenberg A.J. Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res. 60:2000;2399-2404.
112. Nathan C.A., Leskov I.L., Lin M., Abreo F.W., Shi R., Hartman G.H., Glass J. Cox-2 expression in dysplasia of the head and neck. correlation with elF4E Cancer. 92:2001;1888-1895.
113. Howe L.R., Dannenberg A.J. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol. 29:2002;111-119.
114. Rosin M.P., Cheng X., Poh C.F., Lam W.L., Huang Y., Lovas J., Berean K., Epstein J.B., Priddy R., Le N.D., Zhang L. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 6:2000;357-362.
115. Mao L., Lee J.S., Fan Y.H., Ro J.Y., Batsakis J.G., Lippman S., Hittelman W., Hong W.K. Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Med. 2:1996;682-685.
116. Partridge M., Pateromichelakis S., Phillips E., Emilion G.G., A'Hern R.P., Langdon J.D. A case control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res. 60:2000;3893-3898.
117. Lee J.J., Hong W.K., Hittelman W.N., Mao L., Lotan R., Shin D.M., Benner S.E., Xu X.C., Lee J.S. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 6:2000;1702-1710.
118. Califano J., Westra W.H., Meininger G., Corio R., Koch W.M., Sidransky D. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res. 6:2000;347-352.
119. Cairns P., Sidransky D. Molecular methods for the diagnosis of cancer. Biochimica et Biophysica Acta. 1423(2):1999;C11-C18.
120. Ahrendt S.A., Sidransky D. The potential of molecular screening. Surg Oncol Clinics of N Am. 8:1999;641-656.
121. Mao L. Can molecular assessment improve classification of head and neck premalignancy? Clin Cancer Res. 6:2000;321-322.
122. Spafford M.F., Koch W.M., Reed A.L., Califano J.A., Xu L.H., Eisenberger C.F., Yip L.et al. Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin Cancer Res. 7:2001;607-612.
123. Rosin M.P., Epstein J.B., Berean K., Durham S., Hay J., Cheng X., Zeng T., Huang Y., Zhang L. The use of exfoliative cell samples to map clonal genetic alterations in the oral epithelium of high-risk patients. Cancer Res. 57(23):1997;5258-5260.
124. Mao L., El-Naggar A.K., Papadimitrakopoulou V., Shin D.M., Shin H.C., Fan Y., Zhou X., Clayman G., Lee J.J., Lee J.S., Hittelman W.N., Lippman S.M., Hong W.K. Phenotype and genotype of advanced premalignant head and neck lesions after chemotherapeutic therapy. J Natl Cancer Inst. 90:1998;1545-1551.
125. Onderly F.G., Junn S.K., Adams G.L. Inhibition of head and neck tumor cell growth with arachadonic acid metabolism inhibition. Laryngoscope. 106:1996;129-134.
126. Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. Med. 340:1999;1888-1899.
127. Dzielska-Olczak S. Clinical application of cyclooxygenase-2 inhibitors. Pol Merkuriusz Lek. 10:2001;480-482.
128. Goldstein J.L., Silverstein F.E., Agrawal N.M., Hubbard R.C., Kaiser J., Maurath C.J. Reduced risk of upper gastrointestinal ulcer complications with Celecoxib. a novel Cox-2 inhibitor Am Gastroenterol. 95:2000;1681-1690.
129. Geis G.S. Update on clinical development with celecoxib, a new specific cox-2 inhibitor. What can we expect? J Rheumatol. 26:1999;32-36.
130. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S.et al. Antiangiogenic and anti-tumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311.
131. Kenyon B.M., Voest E.E., Chen C.C., Flynn E., Folkman J., Damato R.J. A model of angiogenesis in the mouse cornea. Invest Opthalmol Vis Sci. 37:1996;1625-1632.